Pharmacology/Pharmaceutical Industry
Editorial – SARS-CoV2 Vaccines: Slow is Fast
25 May, 2020 | 01:54h | UTCSARS-CoV2 vaccines: Slow is fast – Science
Promising Early Results with New Vaccine from China in Phase I Trial
25 May, 2020 | 01:57h | UTCCommentaries: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response – The Lancet AND Early Study Of Covid-19 Vaccine Developed In China Sees Mixed Results – Forbes AND Coronavirus Vaccine Shows Promising Early Results in China – The New York Times AND A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials – Business Insider AND Experts skeptical after researchers report positive vaccine results – CNN AND Two COVID-19 Vaccine Candidates Induce Immune Response In Healthy Volunteers – Health Policy Watch
[Abstract Only] Randomized Trial: Haloperidol Effective for the Treatment of Headache in the Emergency Department
25 May, 2020 | 01:33h | UTC
Cohort Study: Fluconazole Use in the First Trimester of Pregnancy Linked to Increased Risk of Musculoskeletal Malformations
25 May, 2020 | 01:31h | UTCCommentary: Musculoskeletal Malformations Up With Fluconazole in Pregnancy – Physician’s Weekly
15 Drugs Being Tested to Treat COVID-19 and How They Would Work
22 May, 2020 | 04:52h | UTC15 drugs being tested to treat COVID-19 and how they would work – Nature
[Preprint] IL6 Inhibition in Critically Ill COVID-19 Patients is Associated with Increased Secondary Infections
22 May, 2020 | 04:44h | UTC
SARS-CoV-2 Infection Protects Against Rechallenge in Rhesus Macaques
21 May, 2020 | 09:27h | UTCSARS-CoV-2 infection protects against rechallenge in rhesus macaques – Science
Related Study: DNA vaccine protection against SARS-CoV-2 in rhesus macaques – Science
Commentaries: Infection With SARS-CoV-2 Protects Against Re-infection – At Least in Rhesus Macaques – Technology Networks AND Prototype Vaccine Protects Monkeys From Coronavirus – The New York Times
Systematic Review: Safety and Adverse Effects of 80 Antidepressants, Antipsychotics, Anti‐attention‐deficit/hyperactivity Medications and Mood Stabilizers in Children and Adolescents
21 May, 2020 | 09:10h | UTC
Editorial: Lack of Efficacy of Hydroxychloroquine in Covid-19
20 May, 2020 | 10:01h | UTCLack of efficacy of hydroxychloroquine in covid-19 – The BMJ
Original Research: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial – The BMJ
Related Meta-analysis (preprint) Hydroxychloroquine in COVID-19: A systematic review and meta-analysis – medRxiv
Meta-Analysis: ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19
20 May, 2020 | 09:50h | UTCRelated Study (Preprint): Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19 – medRxiv
Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody
19 May, 2020 | 04:35h | UTCCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody – Nature
Commentary: Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody – News Medical
Early Data Show Moderna Covid-19 Vaccine Generates Immune Response
19 May, 2020 | 04:29h | UTCEarly data show Moderna Covid-19 vaccine generates immune response – STAT
See also: Moderna Coronavirus Vaccine Trial Shows Promising Early Results – The New York Times AND Expert reaction to Moderna announcement about their phase 1 trial data on their mRNA vaccine (mRNA-1273) candidate against COVID-19 – Science Media Centre
Randomized Trial: No Benefit from Hydroxychloroquine in Patients with Mild to Moderate Covid-19
18 May, 2020 | 02:11h | UTCCommentary: Further evidence does not support hydroxychloroquine for patients with COVID-19 – BMJ
Systematic Review: Risks and Impact of ACE Inhibitors or ARBs on SARS-CoV-2 Infection in Adults
18 May, 2020 | 01:47h | UTC
Study: Use of Renin–angiotensin–aldosterone System Inhibitors Does Not Increase the Risk of COVID-19 Requiring Admission to Hospital
18 May, 2020 | 01:45h | UTCCommentary: Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19 – The Lancet
[Abstract Only] Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
15 May, 2020 | 03:22h | UTC
[Abstract Only] Randomized Trial: Improved Overall Survival with Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
15 May, 2020 | 03:23h | UTCSee also: Visual Abstract
[Abstract Only] Cost–benefit Analysis of Cancer Drugs in the USA and Europe
14 May, 2020 | 02:25h | UTCPrices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries: High cost of cancer drugs not always justified – University of Zurich AND High Cost of Cancer Drugs Does Not Reflect Clinical Benefit – Medscape
Study Commentary – Virus Wars: Return of Lopinavir/Ritonavir (Along with Ribavirin and Interferon)
13 May, 2020 | 02:12h | UTCVirus Wars: Return of Lopinavir/Ritonavir (along with ribavirin and interferon) – PulmCrit
Original Article: Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial (study and commentaries)
Hydroxychloroquine in Patients with COVID-19: A Systematic Review and Meta-analysis
13 May, 2020 | 01:53h | UTC“While initial studies with hydroxychloroquine showed some ray of hope, recent studies that have emerged found either no benefit or a possible harm in COVID-19.”
Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-clinical and Clinical Studies
13 May, 2020 | 01:50h | UTC“While the first double-blind, randomized-controlled trial (DBRCT) found no significant benefit with remdesivir compared to placebo, preliminary reports from another DBRCT showed a significant faster recovery, without any difference in mortality.”
The FDA has Authorized the use of Remdesivir: But There’s no Good Evidence it Reduces Mortality in Covid-19
13 May, 2020 | 01:49h | UTC
Observational Study: Hydroxychloroquine, Azithromycin, or Both Not Associated with Lower In-hospital Mortality
12 May, 2020 | 03:39h | UTC
Perspective: Which COVID-19 Antivirals Actually Work?
12 May, 2020 | 03:18h | UTCPerspective: Which COVID-19 Antivirals Actually Work? – Forbes
Related: Hong Kong Doctors See Progress In Treatment Of COVID-19 – Forbes
Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial
11 May, 2020 | 00:42h | UTCCommentaries: Interferon beta-1b for COVID-19 – The Lancet AND New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial – The Lancet AND A Drug Cocktail Hastens Recovery in Some Coronavirus Patients – The New York Times AND Triple drug therapy helps coronavirus patients recover more quickly, study finds – CNN AND Triple antiviral drug shows early promise in COVID-19 trial – Reuters AND Expert reaction to a study about a phase 2 trial of a triple antiviral drug combination treatment for COVID-19 – Science Media Centre